Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib
NCT06135194 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2023-11-18
Summary
To evaluate the efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
Conditions
Interventions
- DRUG
-
Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
Sponsors & Collaborators
-
Beijing 302 Hospital
lead OTHER
Principal Investigators
-
tao wang · Beijing 302 Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-01
- Primary Completion
- 2023-12-30
- Completion
- 2024-06-30
Countries
- China
Study Locations
More Related Trials
-
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
NCT06722599 ·Status: RECRUITING
-
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
NCT03863223 ·Status: UNKNOWN ·Phase: PHASE3
-
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
NCT05638594 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
NCT03735966 ·Status: COMPLETED ·Phase: PHASE2
-
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
NCT04481932 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
NCT06271837 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
NCT03756064 ·Status: UNKNOWN ·Phase: NA
-
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344793 ·Status: COMPLETED
-
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
NCT07152782 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
NCT06733233 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
NCT06548178 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
NCT06000917 ·Status: RECRUITING ·Phase: PHASE2
-
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
NCT05953168 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
NCT04290793 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
NCT05871918 ·Status: UNKNOWN ·Phase: PHASE3
-
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
NCT06035679 ·Status: RECRUITING ·Phase: NA
-
Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases
NCT04752059 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
NCT06833268 ·Status: COMPLETED
-
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
NCT05577442 ·Status: UNKNOWN ·Phase: PHASE2
-
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
NCT04973319 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer
NCT03847818 ·Status: UNKNOWN ·Phase: NA
-
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
NCT05159193 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04126525 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2